Trishna Goswami
Chief Tech/Sci/R&D Officer at IN8BIO, INC.
Net worth: 5 693 $ as of 2024-06-29
Profile
Dr. Trishna Goswami is a Chief Medical Officer at IN8bio, Inc. Dr. Goswami was previously employed as a Vice President-Clinical Development by Immunomedics, Inc., a Senior Director-Medical by Stemline Therapeutics, Inc., and a Vice President-Clinical Development by Gilead Sciences, Inc. She received her MBA from Robert H.
Smith School of Business and a doctorate degree from Drexel University College of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IN8BIO, INC.
0.02% | 2024-04-16 | 6,729 ( 0.02% ) | 5 693 $ | 2024-06-29 |
Trishna Goswami active positions
| Companies | Position | Start |
|---|---|---|
| IN8BIO, INC. | Chief Tech/Sci/R&D Officer | 2021-11-15 |
Former positions of Trishna Goswami
| Companies | Position | End |
|---|---|---|
| IMMUNOMEDICS, INC. | Corporate Officer/Principal | 2021-11-30 |
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 2018-05-31 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
Training of Trishna Goswami
| Drexel University College of Medicine | Doctorate Degree |
| Robert H. Smith School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| IN8BIO, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Trishna Goswami
